Detection of numerical abnormalities of chromosome 9 and p16/CDKN2A gene alterations in ovarian cancer with fish analysis

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5309-5313

  Aravidis, Christos ^a   Panani, Anna D ^a   Kosmaidou, Zoi ^b   Thomakos, Nikolaos ^a   Rodolakis, Alexandros ^a   Antsaklis, Aristeidis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

Author keywords

Chromosome 9 numerical abnormalities; FISH technique; Genetic changes; Ovarian cancer; p16CDKN2A gene deletion

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; PROTEIN P16; PROTEIN P21; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER CELL; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HUMAN CELL; MONOSOMY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; GENE DELETION; GENES, P16; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 84872511458     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Wang N: Cytogenetics and molecular genetics of ovarian cancer. Am J Med Genet 115: 157-163, 2002.
2. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366(6456): 704-707, 1993.
3. Fåhraeus R, Ball K, Laín S, Lane D and David P: Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr Biol 6(1): 84-91, 1996.
4. INK4a Nature 395(6699): 237-243, 1998.
5. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D and Sidransky D: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11: 210-212, 1995.
6. Campbell G, Beynon G, Davis M and Englefield P: LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int J Cancer 63: 222-225, 1995.
7. Herman J, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson N, Sidransky D and Baylin S: Inactivation of the CDKN2/p16/MTSJ gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995.
8. Shih C, Kerr J, Liu J, Hurst T, Khoo K, Ward B, Wainwright B and Chenevix-Trench G: Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours. Int J Cancer 70: 508-511, 1997.
9. Puig S, Ruiz A, Lazaro C, Castel T, Lynch M, Palou J, Vilalta A, Weissenbach J, Mascaro JM and Estivill X: Chromosome 9p deletions in cutaneous malignant melanoma tumors: The minimal deleted region involves markers outside the p16 (CDKN2) gene. Am J Hum Genet 57: 395-402, 1995.
10. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ and Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8: 27-32, 1994.
11. Williamson P, Elder A, Shaw E, Devlin J and Knowles MA: p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4: 1569-1577, 1995.
12. CDKN2A gene deletion detected by FISH in non-small cell lung cancer. Anticancer Res 29: 4483-4487, 2009.
13. Barbieri F, Cagnoli M, Ragni N, Foglia G, Bruzzo C, Pedullà F and Alama A: Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res 5: 1837-1842, 1999.
14. Dhar KK, Branigan K, Parkes J, Howells RE, Hand P, Musgrove C, Strange RC, Fryer AA, Redman CW, Hoban PR: Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells. Br J Cancer 81: 1174-1181, 1999.
15. Todd MC, Sclafani RA and Langan TA: Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein. Oncogene 19: 258-264, 2000.
16. Rosenberg E, Demopoulos RI, Zeleniuch-Jacquotte A, Yee H, Sorich J, Speyer JL, Newcomb EW: Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum Pathol 32: 808-813, 2001.
17. Hopman AH, Ramaekers FCS, Raap AK, Beck JLM, Devilee P, Ploeg M and Vooijs GP: In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry 89: 307-316, 1988.
18. INK4a in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 74: 57-63, 1997.
19. Kusume T, Tsuda H, Kawabata M, Inoue T, Umesaki N, Suzuki T and Yamamoto K: The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res 5: 4152-4157, 1999.
20. Sui L, Dong Y, Ohno M, Goto M, Inohara T, Sugimoto K, Tai Y, Hando T and Tokuda M: Inverse expression of Cdk4 and p16 in epithelial ovarian tumors. Gynecol Oncol 79: 230-237, 2000.
21. KIP1, cyclin E, and cyclin D2, in ovarian cancer. Int J Gynecol Pathol 22: 168-174, 2003.
22. INK4a overexpression is associated with poor clinical outcome in ovarian cancer. J Chemother 16: 411-413, 2004.
23. Hashiguchi Y, Tsuda H, Inoue T, Nishimura S, Suzuki T and Kawamura N: Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum Pathol 35: 165-175, 2004.
24. INK4a and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br J Cancer 96: 306-313, 2007.
25. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994.
26. Rodabaugh KJ, Biggs RB, Qureshi JA, Barrett AJ, Welch WR, Bell DA, Berkowitz RS and Mok SC: Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. Oncogene 11: 1249-1254, 1995.
27. Watson JE, Gabra H, Taylor KJ, Rabiasz GJ, Morrison H, Perry P, Smyth JF and Porteous DJ: Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis. Genome Res 9: 226-233, 2009.